Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

410 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A lung cancer diagnosis and treatment dataset with geno- and phenotypical characteristics of the patient.
Ríos-Sánchez B, Vigueras G, García A, Gómez-Bravo D, Menasalvas E, Torrente M, Parejo C, Aisopos F, Vogiatzis D, Purohit D, Provencio M, Vidal ME, Rodríguez-González A. Ríos-Sánchez B, et al. Among authors: provencio m. Data Brief. 2024 Nov 23;57:111167. doi: 10.1016/j.dib.2024.111167. eCollection 2024 Dec. Data Brief. 2024. PMID: 39736907 Free PMC article.
Optimizing genetic testing strategy for suspected attenuated adenomatous polyposis: effective solutions in public health systems.
García-Simón N, Valentín F, Royuela A, Hidalgo-Calero B, Blázquez-Martín R, de-Miguel-Reyes M, Sánchez-Zapardiel JM, Adán-Merino L, Rodríguez-Festa A, Gallego-Gil P, Mediavilla-Medel P, Quiñonero-Moreno L, Gutiérrez L, Herreros-de-Tejada A, Sánchez A, Provencio M, Romero A. García-Simón N, et al. Among authors: provencio m. Clin Transl Oncol. 2024 Dec 11. doi: 10.1007/s12094-024-03811-y. Online ahead of print. Clin Transl Oncol. 2024. PMID: 39661238
DSTYK Inhibition Sensitizes NSCLC to Taxane-Based Chemotherapy.
Echepare M, Picabea B, Arricibita A, Teijeira Á, Pasquier A, Zandueta C, Otegui N, Santamaría E, Fernández-Irigoyen J, Romero O, Sanchez-Cespedes M, Lecanda F, Hernández J, Felip E, Cruz-Bermúdez A, Provencio M, Gentili M, Facchinetti F, Roz L, Montuenga LM, Valencia K. Echepare M, et al. Among authors: provencio m. J Thorac Oncol. 2024 Nov 12:S1556-0864(24)02438-9. doi: 10.1016/j.jtho.2024.11.003. Online ahead of print. J Thorac Oncol. 2024. PMID: 39536877
Perioperative chemoimmunotherapy induces strong immune responses and long-term survival in patients with HLA class I-deficient non-small cell lung cancer.
Molina-Alejandre M, Perea F, Calvo V, Martinez-Toledo C, Nadal E, Sierra-Rodero B, Casarrubios M, Casal-Rubio J, Martinez-Martí A, Insa A, Massuti B, Viteri S, Barneto Aranda I, Rodriguez-Abreu D, de Castro J, Martínez JM, Cobo M, Wistuba II, Parra ER, Martín-López J, Megías D, Muñoz-Viana R, Garrido F, Aptsiauri N, Ruiz-Cabello F, Provencio M, Cruz-Bermúdez A. Molina-Alejandre M, et al. Among authors: provencio m. J Immunother Cancer. 2024 Oct 20;12(10):e009762. doi: 10.1136/jitc-2024-009762. J Immunother Cancer. 2024. PMID: 39428126 Free PMC article.
Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial.
Provencio M, Nadal E, Insa A, García Campelo R, Casal J, Dómine M, Massuti B, Majem M, Rodríguez-Abreu D, Martínez-Martí A, de Castro J, Gómez de Antonio D, Macia I, Figueroa S, Fernández Vago L, Calvo V, Palmero R, Sierra-Rodero B, Martínez-Toledo C, Molina-Alejandre M, Serna-Blasco R, Romero A, Cruz-Bermúdez A. Provencio M, et al. Lancet Oncol. 2024 Nov;25(11):1453-1464. doi: 10.1016/S1470-2045(24)00498-4. Epub 2024 Oct 14. Lancet Oncol. 2024. PMID: 39419061 Free PMC article. Clinical Trial.
Certification system for multidisciplinary thoracic tumour boards.
Provencio M, Arenas-Jiménez JJ, Cilleruelo Ramos A, Fernández Villar A, Gómez Caamaño A, Guirado M, Marqués JA, Pijuan L, Sánchez A, Teixidó C, Massutí B; Spanish Lung Cancer Group (SLCG/GECP). Provencio M, et al. Clin Transl Oncol. 2024 Oct 1. doi: 10.1007/s12094-024-03718-8. Online ahead of print. Clin Transl Oncol. 2024. PMID: 39354268
ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial.
Soo RA, Dafni U, Han JY, Cho BC, Nadal E, Yeo CM, Carcereny E, de Castro J, Sala MA, Coate L, Provencio M, Britschgi C, Vagenknecht P, Dimopoulou G, Kammler R, Finn SP, Peters S, Stahel RA; ETOP 10-16 BOOSTER Collaborators. Soo RA, et al. Among authors: provencio m. Clin Cancer Res. 2024 Nov 15;30(22):5180-5191. doi: 10.1158/1078-0432.CCR-24-0932. Clin Cancer Res. 2024. PMID: 39250635 Clinical Trial.
Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study.
Ahn MJ, Tanaka K, Paz-Ares L, Cornelissen R, Girard N, Pons-Tostivint E, Vicente Baz D, Sugawara S, Cobo M, Pérol M, Mascaux C, Poddubskaya E, Kitazono S, Hayashi H, Hong MH, Felip E, Hall R, Juan-Vidal O, Brungs D, Lu S, Garassino M, Chargualaf M, Zhang Y, Howarth P, Uema D, Lisberg A, Sands J; TROPION-Lung01 Trial Investigators. Ahn MJ, et al. J Clin Oncol. 2024 Sep 9:JCO2401544. doi: 10.1200/JCO-24-01544. Online ahead of print. J Clin Oncol. 2024. PMID: 39250535
Quality of care assessment for non-small cell lung cancer patients: transforming routine care data into a continuous improvement system.
Sánchez JC, Nuñez-García B, Garitaonaindia Y, Calvo V, Blanco M, Ramos Martín-Vegue A, Royuela A, Manso M, Cantos B, Méndez M, Collazo-Lorduy A, Provencio M. Sánchez JC, et al. Among authors: provencio m. Clin Transl Oncol. 2024 Aug 16. doi: 10.1007/s12094-024-03658-3. Online ahead of print. Clin Transl Oncol. 2024. PMID: 39147937
410 results